Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

In conclusion, there is no evidence of a reduced efficacy of natalizumab in an EID setting. This observation confirms previous results and together with the emerging evidence of a reduced risk of PML associated to an EID, supports the need of a randomized study to assess the need to change the standard of the natalizumab dosing schedule.
Source: Neurotherapeutics - Category: Neurology Source Type: research